Inna Y Gong1, Andrew T Yan1,2, Craig C Earle1,3,4,5, Maureen E Trudeau1,4, Andrea Eisen1,4, Kelvin K W Chan6,7,8,9,10. 1. Department of Medicine, University of Toronto, Toronto, ON, Canada. 2. St. Michael's Hospital, Toronto, ON, Canada. 3. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 4. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 5. Ontario Institute for Cancer Research, Toronto, ON, Canada. 6. Department of Medicine, University of Toronto, Toronto, ON, Canada. kelvin.chan@sunnybrook.ca. 7. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. kelvin.chan@sunnybrook.ca. 8. Cancer Care Ontario, Toronto, Canada. kelvin.chan@sunnybrook.ca. 9. Canadian Centre for Applied Research in Cancer Control, Vancouver, Canada. kelvin.chan@sunnybrook.ca. 10. Sunnybrook Odette Cancer Centre, University of Toronto, T-Wing, 2075 Bayview Avenue, T2-058, Toronto, ON, M2N3E6, Canada. kelvin.chan@sunnybrook.ca.
Abstract
PURPOSE: Little data exist for comparing cardiac safety and survival outcomes of trastuzumab/pertuzumab or ado-T emtansine (TDM1) in metastatic breast cancer (MBC) patients enrolled in randomized clinical trial (RCT) vs the real-world. METHODS: This was a retrospective population-based cohort of all patients with MBC treated withtrastuzumab/pertuzumab or TDM1 (2012-2017) in Ontario, Canada. Outcomes were incident heart failure (HF) and overall survival (OS). RCT data were obtained from digitizing survival curves and compared with cohort data using Kaplan-Meier analysis. Age-based comparison of outcomes was conducted for patients ≥ 65 years old vs younger than 65. RESULTS: The two cohorts composed of 833 and 397 patients treated with trastuzumab/pertuzumab and TDM1, of whom 5.5% and 7.6% had baseline HF, respectively. Incident HF following trastuzumab/pertuzumab or TDM1 was low (trastuzumab/pertuzumab 1.8 events/100 person years; TDM1 0.02 events/100 person years). The median OS was 39.2 and 56.4 months in the trastuzumab/pertuzumab population-based cohort and CLEOPATRA, respectively. The median OS was 15.4 and 30.9 months in the TDM1 population-based cohort and EMILIA, respectively. Cohort OS was significantly worse than RCT OS (trastuzumab/pertuzumab HR 1.67, 95% CI 1.37-2.03, p < 0.0001; TDM1 HR 2.80, 95% CI 2.27-3.44, p < 0.0001). Older patients had worse OS than younger patients for trastuzumab/pertuzumab (HR 1.60, 95% CI 1.19-2.16, p = 0.0018), but not for TDM1 (HR 1.16, 95% CI 0.81-1.66, p = 0.43). CONCLUSION:HF incidence during trastuzumab/pertuzumab or TDM1 therapy in this real-world cohort was low. Survival in this cohort was worse compared to RCT, suggesting that recruitment of patients similar to the real-world population is required.
RCT Entities:
PURPOSE: Little data exist for comparing cardiac safety and survival outcomes of trastuzumab/pertuzumab or ado-T emtansine (TDM1) in metastatic breast cancer (MBC) patients enrolled in randomized clinical trial (RCT) vs the real-world. METHODS: This was a retrospective population-based cohort of all patients with MBC treated with trastuzumab/pertuzumab or TDM1 (2012-2017) in Ontario, Canada. Outcomes were incident heart failure (HF) and overall survival (OS). RCT data were obtained from digitizing survival curves and compared with cohort data using Kaplan-Meier analysis. Age-based comparison of outcomes was conducted for patients ≥ 65 years old vs younger than 65. RESULTS: The two cohorts composed of 833 and 397 patients treated with trastuzumab/pertuzumab and TDM1, of whom 5.5% and 7.6% had baseline HF, respectively. Incident HF following trastuzumab/pertuzumab or TDM1 was low (trastuzumab/pertuzumab 1.8 events/100 person years; TDM1 0.02 events/100 person years). The median OS was 39.2 and 56.4 months in the trastuzumab/pertuzumab population-based cohort and CLEOPATRA, respectively. The median OS was 15.4 and 30.9 months in the TDM1 population-based cohort and EMILIA, respectively. Cohort OS was significantly worse than RCT OS (trastuzumab/pertuzumab HR 1.67, 95% CI 1.37-2.03, p < 0.0001; TDM1 HR 2.80, 95% CI 2.27-3.44, p < 0.0001). Older patients had worse OS than younger patients for trastuzumab/pertuzumab (HR 1.60, 95% CI 1.19-2.16, p = 0.0018), but not for TDM1 (HR 1.16, 95% CI 0.81-1.66, p = 0.43). CONCLUSION:HF incidence during trastuzumab/pertuzumab or TDM1 therapy in this real-world cohort was low. Survival in this cohort was worse compared to RCT, suggesting that recruitment of patients similar to the real-world population is required.
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: K David Voduc; Maggie C U Cheang; Scott Tyldesley; Karen Gelmon; Torsten O Nielsen; Hagen Kennecke Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Elizabeth B Lamont; Mary Beth Landrum; Nancy L Keating; Laura Archer; Lan Lan; Gary M Strauss; Rogerio Lilenbaum; Harvey B Niell; L Herbert Maurer; Michael P Kosty; Antonius A Miller; Gerald H Clamon; Anthony D Elias; Edward F McClay; Everett E Vokes; Barbara J McNeil Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Stephen K Chia; Caroline H Speers; Yulia D'yachkova; Anna Kang; Suzanne Malfair-Taylor; Jeff Barnett; Andy Coldman; Karen A Gelmon; Susan E O'reilly; Ivo A Olivotto Journal: Cancer Date: 2007-09-01 Impact factor: 6.860
Authors: Wei Fang Dai; Jaclyn M Beca; Chenthila Nagamuthu; Ning Liu; Claire de Oliveira; Craig C Earle; Maureen Trudeau; Rebecca E Mercer; Kelvin K W Chan Journal: JAMA Netw Open Date: 2022-02-01
Authors: Vanessa Arciero; Jin Luo; Ambica Parmar; Wei Fang Dai; Jaclyn M Beca; Michael J Raphael; Wanrudee Isaranuwatchai; Steven Habbous; Mina Tadrous; Craig C Earle; Jim J Biagi; Nicole Mittmann; Jessica Arias; Scott Gavura; Kelvin K W Chan Journal: JNCI Cancer Spectr Date: 2022-07-01